Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17224675 | 0.90 | CYP2C19 (0.51) | KDM4ECYP2C19ALDH1A1USP2HPGD | |
| SCHEMBL1994152 | 0.86 | KDM4E (0.71) | KDM4ECYP2C19ALDH1A1USP2HPGD | |
| SCHEMBL15454581 | 0.86 | CES2 (0.55) | KDM4ECYP2C19ALDH1A1USP2HPGD | |
| SCHEMBL13163895 | 0.85 | ALDH1A1 (0.47) | KDM4ECYP2C19ALDH1A1USP2HPGD | |
| SCHEMBL15453599 | 0.83 | CES2 (0.49) | KDM4ECYP2C19ALDH1A1USP2HPGD | |
| SCHEMBL24436810 | 0.83 | KDM4E (0.46) | KDM4ECYP2C19ALDH1A1USP2HPGD | |
| SCHEMBL1714974 | 0.83 | KDM4E (0.62) | KDM4ECYP2C19ALDH1A1USP2HPGD | |
| SCHEMBL3325352 | 0.83 | MRGPRX4 (0.47) | KDM4ECYP2C19ALDH1A1USP2HPGD | |
| SCHEMBL24436827 | 0.83 | KDM4E (0.62) | KDM4ECYP2C19ALDH1A1USP2HPGD | |
| SCHEMBL28062602 | 0.82 | CES2 (0.47) | KDM4ECYP2C19ALDH1A1USP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025110780-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS DNA POLYMERASE THETA INHIBITORS FOR THE PREVENTION OR TREATMENT OF CANCER | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-05-30 | — | — | WO | disclosed |
| US-20130244122-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | ONUKI MASAMICHI (JP) | 2013-09-19 | — | — | US | disclosed |
| WO-2013018929-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-07 | — | — | WO | disclosed |
| US-20120219866-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2475041-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME | Mitsubishi Chemical Corporation (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-7338959-B2 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | disclosed |
| EP-0907644-A4 | PHARMACEUTICAL PREPARATION | MERCK & CO INC (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-0776208-B1 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO INC (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0907644-A1 | PHARMACEUTICAL PREPARATION | Merck & Co., Inc. (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049690-A1 | A METHOD FOR TREATING MENIERE'S DISEASE | MERCK & CO., INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0776203-A4 | N-2,3-DIHYDRO-1-(2-PROPYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO INC (US) | 1997-12-29 | — | — | EP | disclosed |
| EP-0776208-A4 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO INC (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1997048686-A1 | NOVEL N-1 ALKYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPIN-3-YL)-3-AMIDES | MERCK & CO., INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| US-5658901-A | 2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines | MERCK & CO., INC. (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0776208-A1 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO. INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| EP-0776203-A1 | N-2,3-DIHYDRO-1-(2-PROPYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO. INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| US-5633251-A | N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1996005827-A1 | N-2,3-DIHYDRO-1-(2-PROPYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO., INC. (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1996005839-A1 | 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES | MERCK & CO., INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | TIE1, TEK, KDR | KDM4E 617/4885CYP2C19 3287/4885ALDH1A1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.